
Sign up to save your podcasts
Or


A woman's public coverage for cancer drug Keytruda was denied, largely, it seems, on the basis that too few cancer patients have survived long enough to justify coverage beyond two years.
Guest: Richard Zussman - Global News Legislative Reporter
Learn more about your ad choices. Visit megaphone.fm/adchoices
By CKNW / CuriouscastA woman's public coverage for cancer drug Keytruda was denied, largely, it seems, on the basis that too few cancer patients have survived long enough to justify coverage beyond two years.
Guest: Richard Zussman - Global News Legislative Reporter
Learn more about your ad choices. Visit megaphone.fm/adchoices

16,220 Listeners

36,617 Listeners

199 Listeners

67 Listeners

8 Listeners

9 Listeners

4 Listeners

1 Listeners

1 Listeners

0 Listeners

86 Listeners

222 Listeners

78 Listeners

551 Listeners

13,687 Listeners

96 Listeners

1,725 Listeners

47,654 Listeners

17 Listeners

5 Listeners

8 Listeners

5 Listeners

10 Listeners

603 Listeners

3 Listeners

112 Listeners

54 Listeners

10,745 Listeners

41 Listeners

1 Listeners

0 Listeners

51 Listeners

4 Listeners